Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,359 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: FAST alone Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food

NCT07404137
View directory record Official record
Conditions
Healthy Participants
Interventions
Zibotentan/Dapagliflozin FDC
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-016)

NCT06772805
View directory record Official record
Conditions
Healthy
Interventions
Nemtabrutinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose Pharmacokinetics and Safety of Oral Lofexidine in Hepatically-Impaired Subjects

NCT02318836
View directory record Official record
Conditions
Liver Failure
Interventions
Lofexidine Hydrochloride (HCl) tablets
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study on the Pharmacokinetics (PK) of DFN-15 vs Comparator and Food-effect on DFN-15 PK in Healthy Adult Subjects

NCT03282838
View directory record Official record
Conditions
Migraine
Interventions
DFN-15 (fasted), DFN-15 (fed), Comparator Celebrex® (fed)
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir

NCT03095638
View directory record Official record
Conditions
HIV Infections
Interventions
Conventional dolutegravir 10 mg tablet, Conventional dolutegravir 50 mg tablet, Dispersible dolutegravir 5 mg tablet, Conventional dolutegravir 25 mg tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 24, 2026, 9:21 PM EDT
Terminated Phase 2 Interventional

A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

NCT02109016
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, NSCLC, Small Cell Lung Cancer, SCLC, Lung Cancer, Advanced Lung Cancer, Metastatic Lung Cancer, Stage IV Lung Cancer
Interventions
Lucitanib
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 24, 2026, 9:21 PM EDT
Completed No phase listed Observational

BIONICS - Pharmacokinetics (PK) Trial

NCT02736344
View directory record Official record
Conditions
Heart Disease
Interventions
BioNIR Ridaforolimus Eluting Coronary Stent
Device
Lead sponsor
Medinol Ltd.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Scottsdale, Arizona • Petoskey, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan

NCT00969449
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Naproxen Sodium, (BAY H6689), Naprelan, (BAY H6689)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Isotretinoin Capsules 40 mg Under Fasting Condition

NCT01888289
View directory record Official record
Conditions
Healthy
Interventions
Isotretinoin
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Quadrangle Drive, Chapel Hill,, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 27, 2013 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects

NCT02412449
View directory record Official record
Conditions
Healthy
Interventions
AKB-6548 tablet, reference formulation given in the fasted state, AKB-6548 tablet, test formulation given in the fasted state., AKB-6548 tablet, test formulation given in the fed state
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 1 Interventional

TAK-329 Glucose Clamp Study

NCT01311076
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
TAK-329, Insulin, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 50 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Oct 24, 2026, 9:21 PM EDT
Not yet recruiting Phase 3 Interventional

Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)

NCT06525389
View directory record Official record
Conditions
Talaromycosis
Interventions
Liposomal Amphotericin B (LAmB), Flucytosine (5FC), Flucytosine (5FC) placebo pill, Deoxycholate Amphotericin B (DAmB)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Effectiveness of the RAP Device for the Improvement in the Appearance of Cellulite

NCT05199506
View directory record Official record
Conditions
Cellulite
Interventions
RAP
Device
Lead sponsor
Soliton
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of Omaveloxolone in Healthy Volunteers

NCT03664453
View directory record Official record
Conditions
Healthy
Interventions
omaveloxolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 24, 2026, 9:21 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers Results available

Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening

NCT04877912
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI Abbreviated Scan, Abbreviated MRI Scan
Diagnostic Test
Lead sponsor
University of Chicago
Other
Eligibility
40 Years to 74 Years · Female only
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 24, 2026, 9:21 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Temporal Interference for Thalamocortical Activity and Network Modulation

NCT07219719
View directory record Official record
Conditions
Healthy Participants
Interventions
Temporal Interference Transcranial electrical stimulation (TI-TES), Sham stimulation
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Crossover Study of the Safety and PK Properties of Proellex®

NCT00749879
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 34 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg

NCT00649623
View directory record Official record
Conditions
Healthy
Interventions
Olmesartan Medoxomil Tablets 40 mg, Benicar® Tablets 40 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Albuterol Sulfate Extended-Release Tablets 8 mg and VoSpire® ER Tablets 8 mg

NCT00649779
View directory record Official record
Conditions
Healthy
Interventions
albuterol sulfate extended-release 8 mg tablets, VoSpire™ ER 8 mg tablets
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 1, 2008 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes

NCT00835861
View directory record Official record
Conditions
Non Insulin Dependent Diabetes, Pregnancy
Interventions
Metformin, Insulin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 24, 2026, 9:21 PM EDT
Not yet recruiting Phase 2 Interventional

Zavegepant Intranasal Spray for the Acute Treatment of Episodic Cluster Headache

NCT07714369
View directory record Official record
Conditions
Cluster Headache
Interventions
Zavegepant 20 mg
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect

NCT04077879
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ASP1617, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 24, 2026, 9:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

PreDM Clinical Decision Support Intervention

NCT04335331
View directory record Official record
Conditions
PreDiabetes
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
7,424 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers

NCT02634073
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Lamivudine, Sorbitol
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 24, 2026, 9:21 PM EDT